Ant International’s Risk Tech Solutions Win WDTA AI STR-02 Certification
At the DWC AI STR Forum (Digital World Conference: AI Safety, Trust, and Responsibility Forum) by The World Digital Technology Academy (WDTA) in Hong Kong, AlipayHK became one of the first global tech operators to obtain a security certification on Large Language Model (LLM) applications in compliance with WDTA AI STR-02 Standards. This certification testifies to the strength of risk tech capabilities of Ant International, and marks a significant step in AI governance for Hong Kong.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250305979238/en/
Dr Tianyi Zhang, General Manager of Global Risk Management and Cybersecurity at Ant International speaking at the Global AI Action Summit in Hong Kong (Photo: Business Wire)
WDTA, a non-governmental organization operating under the UN framework, issues The LLM Security Certification as part of its AI Safety, Trust, and Responsibility (AI STR) series of standards. This certification effectively identifies and assesses issues and risks, such as data leaks, model tampering, and supplier non-compliance, throughout the entire lifecycle of large models.
Dr Tianyi Zhang, General Manager of Global Risk Management and Cybersecurity at Ant International, says: “This certification demonstrates that our ecosystem's AI capabilities are not only technologically innovative, but also integrate safety, reliability, and controllability throughout the product development process. I am glad we’ve been able to balance risk prevention, user experience, and cost in a real-world product that serves millions of users.”
By leveraging Ant International's Risk S.H.I.E.L.D (Security with High standard, Intelligent Efficiency, Lean and Dependability) strategy, AlipayHK provides 24/7 real-time risk detection and scanning, ensuring the security of user accounts and transactions. The AI-based risk control algorithm models enable dynamic risk identification and adjustment. Adaptive strategy optimization allows for flexible responses to complex and changing risk situations, providing rock-solid security protection and building a strong defense for user accounts and funds.
The large model safeguard system conducts 500,000 automated assessments daily, comprehensively identifying security vulnerabilities from dimensions such as data security, content security, and technological ethics.
- 24/7 Security Scanning: Using multimodal detection technology, it accurately identifies deepfake content such as face swaps and AIGC-generated synthetic content, and provides authenticity scores for images, audio, and text.
- Intelligent Vulnerability Management: Based on an expert vulnerability database and reachability analysis, it performs in-depth scans of large model files and provides dynamic repair recommendations.
- AI vs. AI: Utilizing large models for real-time decision-making, it blocks new types of attacks such as data leaks and model poisoning.
Ant International is a global integrated TechFin platform headquartered in Singapore, providing cross-border payment and account services for businesses, and expanding into digital growth and scenario-based financial solutions. In 2024, Ant International began operating independently and announced that it will strengthen the application and innovation of AI in the fintech sector to support the growth of emerging markets and small and medium-sized enterprises (SMEs).
Currently, Ant International's risk technology, wallet technology, payment technology, platform technology, and credit technology capabilities serve a network that includes AlipayHK and 35 other global e-wallets. These services cover more than 200 markets, reaching over 1.7 billion consumer accounts and 90 million merchants, and support more than 100 currencies.
About Ant International
Headquartered in Singapore, Ant International powers the future of global commerce with digital innovation for everyone and every business to thrive. In close collaboration with partners, we support merchants of all sizes worldwide to realize their growth aspirations through a comprehensive range of tech-driven digital payment and financial services solutions.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250305979238/en/
Contacts
Media
Chloe Zhu
Jingchong.zhu@antgroup.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom